These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8797468)

  • 1. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease.
    Thal LJ; Carta A; Clarke WR; Ferris SH; Friedland RP; Petersen RC; Pettegrew JW; Pfeiffer E; Raskind MA; Sano M; Tuszynski MH; Woolson RF
    Neurology; 1996 Sep; 47(3):705-11. PubMed ID: 8797468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
    Thal LJ; Calvani M; Amato A; Carta A
    Neurology; 2000 Sep; 55(6):805-10. PubMed ID: 10994000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetyl-L-carnitine (ALCAR) to enhance nerve regeneration in carpal tunnel syndrome: study protocol for a randomized, placebo-controlled trial.
    Curran MW; Olson J; Morhart M; Sample D; Chan KM
    Trials; 2016 Apr; 17():200. PubMed ID: 27079660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.
    Montgomery SA; Thal LJ; Amrein R
    Int Clin Psychopharmacol; 2003 Mar; 18(2):61-71. PubMed ID: 12598816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.
    Rai G; Wright G; Scott L; Beston B; Rest J; Exton-Smith AN
    Curr Med Res Opin; 1990; 11(10):638-47. PubMed ID: 2178869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.
    Pettegrew JW; Klunk WE; Panchalingam K; Kanfer JN; McClure RJ
    Neurobiol Aging; 1995; 16(1):1-4. PubMed ID: 7723928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.
    Youle M; Osio M;
    HIV Med; 2007 May; 8(4):241-50. PubMed ID: 17461852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M
    Neurology; 1991 Nov; 41(11):1726-32. PubMed ID: 1944900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach.
    Brooks JO; Yesavage JA; Carta A; Bravi D
    Int Psychogeriatr; 1998 Jun; 10(2):193-203. PubMed ID: 9677506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
    Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
    Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.
    Sano M; Bell K; Cote L; Dooneief G; Lawton A; Legler L; Marder K; Naini A; Stern Y; Mayeux R
    Arch Neurol; 1992 Nov; 49(11):1137-41. PubMed ID: 1444880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial.
    Malaguarnera G; Catania VE; Bertino G; Chisari LM; Castorina M; Bonfiglio C; Cauli O; Malaguarnera M
    Curr Pharm Des; 2022; 28(38):3158-3166. PubMed ID: 36043711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression.
    Pettegrew JW; Levine J; McClure RJ
    Mol Psychiatry; 2000 Nov; 5(6):616-32. PubMed ID: 11126392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
    Tomassini V; Pozzilli C; Onesti E; Pasqualetti P; Marinelli F; Pisani A; Fieschi C
    J Neurol Sci; 2004 Mar; 218(1-2):103-8. PubMed ID: 14759641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective observational study on the use of acetyl-L-carnitine in ALS.
    Sassi S; Bianchi E; Diamanti L; Tornabene D; Sette E; Medici D; Matà S; Leccese D; Sperti M; Martinelli I; Ghezzi A; Mandrioli J; Iuzzolino VV; Dubbioso R; Trojsi F; Passaniti C; D'Alvano G; Filosto M; Padovani A; Mazzini L; De Marchi F; Zinno L; Nuredini A; Bongioanni P; Dolciotti C; Canali E; Toschi G; Petrucci A; Perna A; Riso V; Inghilleri M; Libonati L; Cambieri C; Pupillo E
    J Neurol; 2023 Nov; 270(11):5344-5357. PubMed ID: 37378756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia].
    Gavrilova SI; Kalyn IaB; Kolykhalov IV; Roshchina IF; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):16-22. PubMed ID: 22027664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.